<DOC>
	<DOCNO>NCT01900509</DOCNO>
	<brief_summary>Participants relapse refractory leukemia lymphoma recruit study find whether addition new drug call bendamustine safe possible give chemotherapy drug . This drug approve Food Drug Administration ( FDA ) treatment cancer adults similar study research trial . PRIMARY OBJECTIVES - To establish maximum tolerate dose ( MTD ) bendamustine combination clofarabine etoposide pediatric participant hematologic malignancy . - To characterize safety profile dose-limiting toxicity ( DLTs ) bendamustine combination clofarabine etoposide . SECONDARY OBJECTIVES - To estimate event-free survival 4 month . - To estimate minimal residual disease ( MRD ) level present end cycle therapy participant leukemia . - To characterize pharmacokinetic profile bendamustine propose regimen .</brief_summary>
	<brief_title>Bendamustine Hydrochloride , Clofarabine , Etoposide Treating Younger Patients With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description>Bendamustine combine clofarabine etoposide five-day cycle . Dexamethasone give prevent capillary leak syndrome associate clofarabine . If participant develop progressive disease dose-limiting toxicity ( DLT ) first cycle , second cycle may administer bridge transplant . Each cycle last 21-28 day ( count recovery ) . Concomitant intrathecal therapy give investigator 's discretion , day chemotherapy . Recommendations triple intrathecal therapy ( methotrexate , hydrocortisone , cytarabine ) weekly participant CNS2 CNS3 disease , every two week participant CNS1 disease . Leucovorin may give accord institutional guideline . The intent study design participant receive complete one course therapy . Participants exhibit sign disease progression experience unacceptable toxicity discontinue protocol treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA Participants Hodgkin NonHodgkin lymphoma must meet one follow criterion : ( ) Relapsing disease 2nd great relapse measurable disease , ( b ) Refractory disease fail achieve complete remission ( CR ) &gt; 2 induction reinduction attempt . Participant acute leukemia must meet one follow criterion : ( ) Relapsing acute lymphoblastic leukemia ( ALL ) , acute myeloid leukemia ( AML ) , acute biphenotypic leukemia 2nd great relapse ; ( b ) Refractory ALL , AML , acute biphenotypic leukemia fail achieve CR ≥ 2 induction reinduction attempt . Participant leukemia M2 M3 marrow time enrollment . Participant M2 marrow must definite cytogenetic , molecular , immunophenotypic evidence recurrent/refractory disease . Age ≤ 21 year ( participant yet reach 22nd birthday ) . Karnofsky Lansky performance score ≥ 60 % . The Lansky performance score use participant &lt; 16 year Karnofsky performance score participant ≥ 16 year . There know contraindication plan agent use protocol . Etoposide may substitute etoposide phosphate ( etopophos ) patient history hypersensitivity reaction etoposide Adequate renal function define glomerular filtration rate &gt; 60 cc/min/1.73m2 , normal serum creatinine base age . Adequate hepatic function : ( ) Direct bilirubin ≤ upper limit normal ( ULN ) age , total bilirubin &gt; ULN , direct bilirubin ≤ 1.4 mg/dl , ( b ) AST ALT ≤ 5 x ULN age . Adequate cardiac function define shorten fraction ≥ 27 % ejection fraction ≥ 45 % . Lymphoma participant without bone marrow involvement must : ( ) Absolute neutrophil count ( ANC ) ≥ 1,000/µL , ( b ) Platelet count &gt; 50,000/mm^3 ( without transfusion support ) . [ Note : criterion waive participant leukemia lymphoma participant bone marrow involvement . ] Participant must recover acute side effect prior anticancer therapy , : At least 2 week elapse since prior systemic cytotoxic chemotherapy ( except intrathecal chemotherapy , and/or low dose maintenance therapy vincristine , mercaptopurine , methotrexate glucocorticoid ) , At least 4 week elapse since treatment investigational agent antibodybased therapy , applicable , If participant receive prior allogeneic hematopoietic stem cell transplantation ( HSCT ) , least 3 month elapse evidence active graftversushost disease ( GVHD ) , participant discontinue immunosuppression , history venoocclusive disease . EXCLUSION CRITERIA Active , uncontrolled infection severe concurrent medical disease , include limited congestive heart failure , cardiac arrhythmia , psychiatric illness . Isolated extramedullary disease ( leukemia ) . Primary CNS lymphoma . Pregnant lactating ( female participant childbearing potential must negative serum urine pregnancy test require within 7 day prior start treatment ) . Known HIV active hepatitis B C infection . Known hypersensitivity bendamustine mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Childhood leukemia</keyword>
	<keyword>Childhood lymphoma</keyword>
	<keyword>Bendamustine</keyword>
</DOC>